Article info
PDFInflammatory bowel disease
Original article
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results
- Correspondence to Dr Tim Wyant, Takeda Pharmaceuticals International Co, 40 Landsdowne St, Cambridge, MA 02139, USA; Tim.Wyant{at}takeda.com
Citation
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results
Publication history
- Received February 25, 2014
- Revised April 2, 2014
- Accepted April 3, 2014
- First published April 24, 2014.
Online issue publication
February 15, 2017
Article Versions
- Previous version (18 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions